GrandRoundsFL19
TARGET AUDIENCE OVERVIEW OF ACTIVITY This video presentation by Dr John P Leonard uses a review of recent relevant publications and presentations, ongoing clinical trials and clinical investigator treatment preferences to assist medical oncologists and other healthcare providers involved in the treatment of FL with the formulation of up-to-date clinical management strategies. LEARNING OBJECTIVES
ACCREDITATION STATEMENT CREDIT DESIGNATION STATEMENT AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC) HOW TO USE THIS CME ACTIVITIES CONTENT VALIDATION AND DISCLOSURES FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process: Presenting Faculty Member John P Leonard, MD Consulting Agreements: ADC Therapeutics SA, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biotest Pharmaceuticals Corporation, Bristol-Myers Squibb Company, Celgene Corporation, Genentech, Gilead Sciences Inc, Juno Therapeutics, Karyopharm Therapeutics, MEI Pharma, Novartis, Pfizer Inc, Sutro Biopharma Inc, United Therapeutics. Project Steering Committee Members Bruce D Cheson, MD Advisory Committee and Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Genentech, Gilead Sciences Inc; Contracted Research: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech, Seattle Genetics. Andrew M Evens, DO, MSc Advisory Committee: Novartis; Consulting Agreements: Merck, Pharmacyclics LLC, an AbbVie Company, Novartis, Spectrum Pharmaceuticals Inc. Christopher R Flowers, MD, MS Consulting Agreements: AbbVie Inc, Bayer HealthCare Pharmaceuticals, Denovo Biopharma, Gilead Sciences Inc, Janssen Biotech Inc, Karyopharm Therapeutics, OptumRx Inc, Pharmacyclics LLC, an AbbVie Company, Spectrum Pharmaceuticals Inc; Contracted Research: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Burroughs Wellcome Fund, Celgene Corporation, Eastern Cooperative Oncology Group, Genentech, Gilead Sciences Inc, Janssen Biotech Inc, National Cancer Institute, Roche Laboratories Inc, Takeda Oncology, TG Therapeutics Inc, The V Foundation for Cancer Research; Uncompensated Consulting: Celgene Corporation, Genentech, Roche Laboratories Inc. Nathan H Fowler, MD Advisory Committee: AbbVie Inc, Bayer HealthCare Pharmaceuticals, Celgene Corporation, Gilead Sciences Inc, Janssen Biotech Inc, Roche Laboratories Inc, TG Therapeutics Inc; Contracted Research: AbbVie Inc, Celgene Corporation, Janssen Biotech Inc, Roche Laboratories Inc, TG Therapeutics Inc. Ann S LaCasce, MD, MMSc Advisory Committee: Humanigen Inc; Consulting Agreement: Seattle Genetics; Data and Safety Monitoring Board/Committee: Bristol-Myers Squibb Company; Institutional Research Funding: Celgene Corporation, Forty Seven Inc, Seattle Genetics. Julie M Vose, MD, MBA Consulting Agreements: Acerta Pharma — A member of the AstraZeneca Group, Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, Genentech, Incyte Corporation, Kite Pharma Inc, Merck Sharp & Dohme Corp, Novartis, Seattle Genetics Inc; Contracted Research: AbbVie Inc, Epizyme Inc, Karyopharm Therapeutics, Legend Biotech, Nordic Nanovector, Novartis, Roche Laboratories Inc, Sandoz Inc, a Novartis Division, Vaniam Group. Andrew D Zelenetz, MD, PhD Advisory Committee: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Genentech, Gilead Sciences Inc, Lymphoma Research Foundation; Consulting Agreements: Adaptive Biotechnologies, Amgen Inc, Celgene Corporation, Genentech, Gilead Sciences Inc, Janssen Biotech Inc, Novartis, Roche Laboratories Inc; Contracted Research: BeiGene, Gilead Sciences Inc, MEI Pharma, Roche Laboratories Inc; Data and Safety Monitoring Board/Committee: BeiGene. EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, Genmab, Genomic Health Inc, Gilead Sciences Inc, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Tolero Pharmaceuticals. RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose. This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors. This activity is supported by educational grants from Bayer HealthCare Pharmaceuticals, Celgene Corporation, Genentech and Gilead Sciences Inc. Hardware/Software Requirements: Release date: September 2019 |